44 results about "Cardiac pathology" patented technology

The invention relates to heart treatment devices and methods for performing diagnostic or therapeutic procedures in the region between a bodily organ and a covering of the bodily organ. The invention can be used for example to perform a diagnostic or therapeutic procedure in the pericardial space.

Among >300 miRNAs known to date, miR-1 is considered muscle-specific. Here we show that that miR-1 overexpressed in individuals with coronary artery disease, and when overexpressed, it exacerbated arrhythmogenesis in both infarcted and normal hearts of rats whereas elimination of miR-1 by its antisense inhibitor relieved it. MiR-1 rendered slowed conduction and depolarized membrane by post-transcriptionally repressing KCNJ2 and GJA1 genes, likely accounting for its arrhythmogenic potential. Thus, miR-1 may have important pathophysiological functions in heart, being a novel antiarrhythmic target useful in the treatment and prevention of various cardiac pathologies.

The present invention provides methods and direct cardiac contact diastolic recoil device to improve diastolic recoil of a heart and includes a biocompatible film attached to or enclosing one or more structural elements that store elastic energy during heart contraction and release energy during heart filling.

The measurement of beat-to-beat QT interval variability (QTV) shows clinical promise for identifying several types of cardiac pathology. However, until now, there has been no device capable of displaying, in real time on a beat-to-beat basis, changes in QTV in all 12 conventional leads in a continuously monitored patient. While several software programs have been designed to analyze QTV, heretofore, such programs have all involved only a few channels (at most) and/or have required laborious user interaction or off-line calculations and post-processing, limiting their clinical utility. This invention discloses a PC-based ECG software program that in real time, acquires, analyzes and displays QTV and PQ interval variability (PQV) in each of the independent channels that constitute the 12-lead conventional and/or Frank X, Y, Z lead ECG. The system also analyzes and displays the QTV and PQV from QT and PQ interval signals that are derived from multiple channels and from singular value decomposition such that the effect of noise and other artifacts on the QTV and PQV results are substantially reduced compared to existing single-channel methods. Moreover, this invention also discloses certain new parameters of T-wave (and QRS and P-wave) morphology, that in initial studies have improved clinical diagnostic utility and/or reproducibility and reliability compared to known existing parameters of T-wave morphology. Finally, it also discloses a method for determining the beat-to-beat variability these T, QRS and P-wave morphologic parameters.

The onset of cardiac pathology can be predicted by first acquiring a plurality of lead values as a function of time for set of electrocardiogram leads and defining a spatial curve from the lead values for at least three leads. A fractal index for the spatial curve is calculated as a function of time and the time rate of change of the fractal index is monitored. A negative time rate of change is indicative of normal cardiac activity, while a positive time rate of change is indicative of pathological cardiac activity.

The present invention provides muscle-derived progenitor cells that show long-term survival following transplantation into body tissues and which can augment soft tissue following introduction (e.g. via injection, transplantation, or implantation) into a site of soft tissue. Also provided are methods of isolating muscle-derived progenitor cells, and methods of genetically modifying the cells for gene transfer therapy. The invention further provides methods of using compositions comprising muscle-derived progenitor cells for the augmentation and bulking of mammalian, including human, soft tissues in the treatment of various cosmetic or functional conditions, including malformation, injury, weakness, disease, or dysfunction. In particular, the present invention provides treatments and amelioration for dermatological conditions, gastroesophageal reflux, vesico-ureteral reflux, urinary incontinence, fecal incontinence, heart failure, and myocardial infarction.

A method and system for electronically classifying a pre-processed heart sound signal of a patient as functional (normal) or pathological is provided. The pre-processed patient heart sound signal is segmentised and features are extracted therefrom (104) to build up a feature vector which is representative of the heart sound signal. The feature vector is then fed to a diagnostic decision support network (105) comprising a plurality of artificial neural networks, each relating to a known heart pathology, which is in turn used to conduct the classification.

A system for heart performance characterization and abnormality detection includes an interface for receiving digitized electrical signals representing blood pressure waveforms over one or more heart beat cycles. The digitized electrical signals comprise, a first digital data sequence representing normal blood pressure of a patient, a second digital data sequence representing random blood pressure of a normal patient and a third digital data sequence representing a potentially abnormal blood pressure of a patient. A complexity processor calculates first, second and third complexity indices for the corresponding first, second and third digital data sequences respectively. A correlation processor uses the calculated first, second and third complexity indices to calculate one or more measures indicating deviation of the potentially abnormal blood pressure of the patient from a normal value.

The invention provides conjugates, comprising an organ, tissue or tumor cell homing molecule linked to a moiety. Such a moiety can be, for example, an oligonucleotide, small interfering RNA, gene, virus, protein, pharmaceutical or detectable agent. In addition the invention provides methods to diagnose or treat a pathology of the muscle or heart, by administrating to a subject having or suspected of having a pathology a molecule or conjugate that homes to, binds to and is taken up by the muscle cells or heart cells.

The present invention provides methods and direct cardiac contact device to improve the diastole phase and the systolic phase of a heart and includes a biocompatible film pneumatic locked to the heart to aid in heart compression and relaxation.

The disclosed method analyzes cardiac electrophysiological signals, including ECG and internal cardiac electrograms, based on multi-level symbolic complexity calculation and multi-dimensional mapping. The results may be used to objectively identify cardiac disorders, differentiate cardiac arrhythmias, characterize pathological severities, and predict life-threatening events. Multi-level symbolization and calculation of the electrophysiological signal is used provide better reliability and analysis resolution for identifying and characterizing cardiac disorders. Adaptive analysis of the cardiac signal complexity enables calculation efficiency and reliability with high SNR, and with low calculation volume and power consumption. One dimension (time or frequency domain) and multi-dimension symbolic analysis is used to provide more information of cardiac pathology and high risk rhythm transition to doctors.

The invention provides among other things methods and kits based on assaying for cardiac troponin autoantibodies, either in conjunction with an assay for cardiac troponin and/or as an independent indicator of cardiac pathology, such as myocarditis, cardiomyopathy, and/or ischemic heart disease. Assay methods of the invention can be employed among other things to identify cardiac pathology, or risk thereof, in subjects who have an autoimmune disease or who are related to an individual with an autoimmune disease. In particular embodiments, the invention also provides a method of determining whether a subject having, or at risk for, a cardiac pathology is a candidate for immunosuppressive therapy or immunoabsorption therapy. The invention also provides kits and kit components that are useful for performing the methods of the invention.

The invention relates to a method for preparing CNPase mutant zebra fish, and confirms that a mutant model can spontaneously generate bradycardia and even heart failure accompanied by severe heart failure. According to the invention, a CRISPR-Cas9 technology is combined with a microinjection technology, CNPase is specifically knocked out, a CNPase mutant F1 generation is prepared, and confirmation is performed through a Sange sequencing method; and through hybridizing and screening, a zebra fish homozygous mutant strain with heart specificity marked with green fluorescence is prepared, and it is confirmed that the CNPase homozygous mutant zebra fish can spontaneously generate cardiac hypertrophy and partially develop to heart failure through cardiology and kinetics indexes. The CNPase mutant zebra fish is prepared, an animal model is provided for researching functions of CNPase, and particularly great convenience is provided for researching related diseases of bradycardia accompanied by severe heart failure.

An interferential current system for cardiac treatment of a patient, includes a controller, a stimulation power supply and a plurality of electrodes. The electrodes supply transcutaneous electrical impulses when supplied power by the stimulation power supply, the plurality of electrodes including at least two electrodes supplying transcutaneous electrical impulses at two different frequencies, the transcutaneous electrical impulses provided at two different frequencies giving rise to at least one beat impulse having an interference frequency. At least one sensor in communication with the controller provides data to the controller indicative of various cardiac pathologic conditions, including but not limited to, rhythm abnormalities, muscle wall contraction abnormalities, and ischemic heart disease abnormalities of the patient. At least one of a timing and an intensity of the transcutaneous electrical impulses is varied by the controller based at least in part upon the data indicative of the aforementioned cardiac pathologies of the patient.